Antibody-drug conjugates (ADCs) are emerging anti-cancer agents.
The folate receptor alpha (FOLRα)-directed ADC mirvetuximab soravtansine recently demonstrated clinical activity in platinum-resistant ovarian cancer, with other ADCs currently in development.
The relative expression of FOLRα and other ADC targets is largely unknown across ovarian cancer histotypes.
